_color.png)
Methodology
The clinical research randomly assigned 69 patients with type 2 diabetes and painful diabetic neuropathy, with 41 patients assigned to the treatment group (MLS® Laser Therapy) and 28 patients assigned to the control group (Sham-Laser).
Patients followed their prescribed diabetes medication and received MLS® treatment as the sole form of therapy. The treatment consisted of 9 sessions over a 3-week period, with three sessions per week. The therapeutic approach was divided into two stages. The first stage involved a scan of the foot of both lower extremities, followed by the treatment of 7 specific areas on each extremity (fibular neck, popliteal fossa, medial and lateral malleolus, mid-gluteal fold, and two on the dorsum of the foot).
Result & Conclusions
*The evaluation consisted of three parts: the baseline visit (T0), the post-treatment visit (T1 - 21 days later), and the follow-up visit at 90 days after the initial treatment (T2).
The treatment group had a significant reduction in pain, with the visual analogue scale (VAS) score decreasing from 5.7 to 2.1 by the end of the treatment cycle. In contrast, the control group showed minimal changes in pain levels, further emphasizing the effectiveness of MLS® Laser Therapy.
In sum, the treatment group exhibited a pain reduction of -63.2% for the post-treatment visit and remained the pain reduction by -56.1% at the follow-up visit at 90 days after the initial treatment.
On the other hand, the control group showed minimal change of -12.7% and didn't last for 90 days after the treatment.
It supports the safety and effectiveness of MLS® laser therapy as a complement to standard treatment for painful diabetic peripheral neuropathy.
Product Used In Research -
MLS® Laser M6 robotic laser
